BIOMAT Database Logo BIOMAT Database Logo

The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells. 2015

Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Victoria, Australia.

Glioma cells release glutamate through expression of system xc-, which exchanges intracellular glutamate for extracellular cysteine. Lack of the excitatory amino acid transporter 2 (EAAT2) expression maintains high extracellular glutamate levels in the glioma microenvironment, causing excitotoxicity to surrounding parenchyma. Not only does this contribute to the survival and proliferation of glioma cells, but is involved in the pathophysiology of tumour-associated epilepsy (TAE). We investigated the role of the peroxisome proliferator activated receptor gamma (PPARγ) agonist pioglitazone in modulating EAAT2 expression in glioma cells. We found that EAAT2 expression was increased in a dose dependent manner in both U87MG and U251MG glioma cells. Extracellular glutamate levels were reduced with the addition of pioglitazone, where statistical significance was reached in both U87MG and U251MG cells at a concentration of ≥ 30 μM pioglitazone (p < 0.05). The PPARγ antagonist GW9662 inhibited the effect of pioglitazone on extracellular glutamate levels, indicating PPARγ dependence. In addition, pioglitazone significantly reduced cell viability of U87MG and U251MG cells at ≥ 30 μM and 100 μM (p < 0.05) respectively. GW9662 also significantly reduced viability of U87MG and U251MG cells with 10 μM and 30 μM (p < 0.05) respectively. The effect on viability was partially dependent on PPARγ activation in U87MG cells but not U251MG cells, whereby PPARγ blockade with GW9662 had a synergistic effect. We conclude that PPARγ agonists may be therapeutically beneficial in the treatment of gliomas and furthermore suggest a novel role for these agents in the treatment of tumour associated seizures through the reduction in extracellular glutamate.

UI MeSH Term Description Entries
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071679 Glycogen Synthase Kinase 3 beta A glycogen synthase kinase-3 type enzyme that functions in ENERGY METABOLISM; EMBRYONIC DEVELOPMENT; and NEUROGENESIS. It is also involved in PROTEIN BIOSYNTHESIS and regulates cell growth and proliferation as a component of the WNT SIGNALING PATHWAY and other signaling pathways. Certain polymorphisms in the GSK3B gene have been associated with PARKINSON DISEASE; ALZHEIMER DISEASE; and BIPOLAR DISORDER. GSK-3beta,GSK3B Protein,GSK3beta,GSK 3beta
D000077205 Pioglitazone A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS. Pioglitazone Hydrochloride,5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione,AD 4833,AD-4833,Actos,U 72107A,U-72107A,U72,107A,AD4833,U72107A
D000813 Anilides Any aromatic amide obtained by acylation of aniline.

Related Publications

Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells.
November 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
Impaired expression of excitatory amino acid transporter 2 (EAAT2) and glutamate homeostasis in canine necrotizing meningoencephalitis.
October 2008, The Journal of veterinary medical science,
Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
Peroxisome proliferator-activated receptor gamma agonist pioglitazone alleviates hemorrhage-induced thalamic pain and neuroinflammation.
November 2023, International immunopharmacology,
Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
The expression of excitatory amino acid transporter 2 (EAAT2) in forensic autopsy cases.
April 2001, Forensic science international,
Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
Peroxisome proliferator-activated receptor gamma: promising target in glioblastoma.
September 2018, Panminerva medica,
Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
September 2008, Journal of the American College of Cardiology,
Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone.
June 2013, The American journal of the medical sciences,
Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
Peroxisome proliferator-activated receptor-γ agonist pioglitazone suppresses experimental autoimmune uveitis.
November 2013, Experimental eye research,
Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats.
January 2007, Pharmacology,
Jared Ching, and Stephanie Amiridis, and Stanley S Stylli, and Andrew R Bjorksten, and Nicole Kountouri, and Thomas Zheng, and Lucy Paradiso, and Rodney B Luwor, and Andrew P Morokoff, and Terence J O'Brien, and Andrew H Kaye
Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes.
October 2009, The Journal of biological chemistry,
Copied contents to your clipboard!